Report cover image

Hemophilia Gene Therapy Market  By Type (Hemophilia A, Hemophilia B) , By End User (Hospitals, Specialty Clinics, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033

Publisher Allied Market Research
Published Oct 01, 2024
Length 280 Pages
SKU # ALMR19510565

Description

Hemophilia Gene Therapy Market  By Type (Hemophilia A, Hemophilia B) , By End User (Hospitals, Specialty Clinics, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033


Hemophilia Gene Therapy Market

The hemophilia gene therapy market was valued at $0.4 billion in 2023 and is projected to reach $3.0 billion by 2033, growing at a CAGR of 23.6% from 2024 to 2033.

Hemophilia is a genetic blood disorder that involves improper coagulation of blood due to deficiency or abnormality in certain clotting factors. Gene therapy for this disease is an innovative approach that includes the delivery of an active copy of the dysfunctional gene responsible for the production of clotting factors. The delivered gene induces the patient’s cells to produce the clotting factors, preventing the requirement for frequent factor replacement infusions. This treatment remains highly reliable as it cures the root cause of the disease, eliminating the risk of reversion.

Advancements in gene transfer technology have enhanced the reliability and efficacy of gene therapies, thereby propelling the development of the market. In addition, the ability of gene therapy to treat the root cause of hemophilia entirely prevents patients from recurrent factor replacement sessions and augments the market growth significantly. Furthermore, upsurge in government support in the form of funding & incentives for boosting the R&D of healthcare and biotechnology has elevated the availability of gene therapy for patients. This acts as a key driver of the hemophilia gene therapy market. A notable therapeutic approach currently being explored by researchers and doctors is gene editing. Genome editing tools such as zinc finger nucleases and transcription activator-like effector nucleases are being used to modify a patient’s DNA to cure the disease. This approach is poised to be trending in the future due to its highly targeted and fast-curing ability.

However, the high cost of gene therapies prevents several budget-sensitive individuals from undergoing the treatment, thereby hampering the development of the market. For instance, the two new gene therapies approved by the U.S. Food and Drug Administration in 2022-2023 have list prices of $2.9 million and 3.5 million. On the contrary, rise in strategic collaborations between pharmaceutical firms, research institutions, and regulatory bodies is anticipated to accelerate therapeutic development & reduce the associated expenses. This surge in collaborations & reduction in expenses is expected to present lucrative opportunities for the market growth.

Segment Review

The hemophilia gene therapy market is segmented into type, end user, and region. On the basis of type, the market is bifurcated into hemophilia A and hemophilia B. Depending on end user, it is divided into hospitals, specialty clinics, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of type, the hemophilia A segment is expected to dominate the market by 2033.

Region wise, North America was the highest revenue generator in 2023.

Competition Analysis

The major players in the global hemophilia gene therapy market include BioMarin Pharmaceutical Inc., Spark Therapeutics, Inc., uniQure N.V., Pfizer Inc., Freeline Therapeutics Holdings plc, Sangamo Therapeutics, Inc., Bioverativ, CSL Behring, Ultragenyx, and Shire Plc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the competitive market.

Key Market Segments

By Type

Hemophilia A
Hemophilia B

By End User

Hospitals
Specialty Clinics
Others

By Region

North America
U.S.
Canada
Mexico
Europe
France
Germany
Italy
Spain
UK
Rest of Europe
Asia-Pacific
China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
LAMEA
Brazil
South Africa
Saudi Arabia
Rest of LAMEA

Key Market Players

BioMarin Pharmaceutical Inc.
Spark Therapeutics, Inc.
uniQure N.V.
Pfizer Inc.
Freeline Therapeutics Holdings plc.
Sangamo Therapeutics, Inc
Bioverativ
CSL Behring
Ultragenyx
Shire Plc

Table of Contents

280 Pages
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: HEMOPHILIA GENE THERAPY  MARKET, BY TYPE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Type
4.2. Hemophilia A
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Hemophilia B
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
CHAPTER 5: HEMOPHILIA GENE THERAPY  MARKET, BY END USER
5.1. Market Overview
5.1.1 Market Size and Forecast, By End User
5.2. Hospitals
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Specialty Clinics
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
5.4. Others
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Size and Forecast, By Region
5.4.3. Market Share Analysis, By Country
CHAPTER 6: HEMOPHILIA GENE THERAPY  MARKET, BY REGION
6.1. Market Overview
6.1.1 Market Size and Forecast, By Region
6.2. North America
6.2.1. Key Market Trends and Opportunities
6.2.2. Market Size and Forecast, By Type
6.2.3. Market Size and Forecast, By End User
6.2.4. Market Size and Forecast, By Country
6.2.5. U.S. Hemophilia Gene Therapy  Market
6.2.5.1. Market Size and Forecast, By Type
6.2.5.2. Market Size and Forecast, By End User
6.2.6. Canada Hemophilia Gene Therapy  Market
6.2.6.1. Market Size and Forecast, By Type
6.2.6.2. Market Size and Forecast, By End User
6.2.7. Mexico Hemophilia Gene Therapy  Market
6.2.7.1. Market Size and Forecast, By Type
6.2.7.2. Market Size and Forecast, By End User
6.3. Europe
6.3.1. Key Market Trends and Opportunities
6.3.2. Market Size and Forecast, By Type
6.3.3. Market Size and Forecast, By End User
6.3.4. Market Size and Forecast, By Country
6.3.5. France Hemophilia Gene Therapy  Market
6.3.5.1. Market Size and Forecast, By Type
6.3.5.2. Market Size and Forecast, By End User
6.3.6. Germany Hemophilia Gene Therapy  Market
6.3.6.1. Market Size and Forecast, By Type
6.3.6.2. Market Size and Forecast, By End User
6.3.7. Italy Hemophilia Gene Therapy  Market
6.3.7.1. Market Size and Forecast, By Type
6.3.7.2. Market Size and Forecast, By End User
6.3.8. Spain Hemophilia Gene Therapy  Market
6.3.8.1. Market Size and Forecast, By Type
6.3.8.2. Market Size and Forecast, By End User
6.3.9. UK Hemophilia Gene Therapy  Market
6.3.9.1. Market Size and Forecast, By Type
6.3.9.2. Market Size and Forecast, By End User
6.3.10. Rest Of Europe Hemophilia Gene Therapy  Market
6.3.10.1. Market Size and Forecast, By Type
6.3.10.2. Market Size and Forecast, By End User
6.4. Asia-Pacific
6.4.1. Key Market Trends and Opportunities
6.4.2. Market Size and Forecast, By Type
6.4.3. Market Size and Forecast, By End User
6.4.4. Market Size and Forecast, By Country
6.4.5. China Hemophilia Gene Therapy  Market
6.4.5.1. Market Size and Forecast, By Type
6.4.5.2. Market Size and Forecast, By End User
6.4.6. Japan Hemophilia Gene Therapy  Market
6.4.6.1. Market Size and Forecast, By Type
6.4.6.2. Market Size and Forecast, By End User
6.4.7. India Hemophilia Gene Therapy  Market
6.4.7.1. Market Size and Forecast, By Type
6.4.7.2. Market Size and Forecast, By End User
6.4.8. South Korea Hemophilia Gene Therapy  Market
6.4.8.1. Market Size and Forecast, By Type
6.4.8.2. Market Size and Forecast, By End User
6.4.9. Australia Hemophilia Gene Therapy  Market
6.4.9.1. Market Size and Forecast, By Type
6.4.9.2. Market Size and Forecast, By End User
6.4.10. Rest of Asia-Pacific Hemophilia Gene Therapy  Market
6.4.10.1. Market Size and Forecast, By Type
6.4.10.2. Market Size and Forecast, By End User
6.5. LAMEA
6.5.1. Key Market Trends and Opportunities
6.5.2. Market Size and Forecast, By Type
6.5.3. Market Size and Forecast, By End User
6.5.4. Market Size and Forecast, By Country
6.5.5. Brazil Hemophilia Gene Therapy  Market
6.5.5.1. Market Size and Forecast, By Type
6.5.5.2. Market Size and Forecast, By End User
6.5.6. South Africa Hemophilia Gene Therapy  Market
6.5.6.1. Market Size and Forecast, By Type
6.5.6.2. Market Size and Forecast, By End User
6.5.7. Saudi Arabia Hemophilia Gene Therapy  Market
6.5.7.1. Market Size and Forecast, By Type
6.5.7.2. Market Size and Forecast, By End User
6.5.8. Rest of LAMEA Hemophilia Gene Therapy  Market
6.5.8.1. Market Size and Forecast, By Type
6.5.8.2. Market Size and Forecast, By End User
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top Winning Strategies
7.3. Product Mapping Of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top Player Positioning, 2023
CHAPTER 8: COMPANY PROFILES
8.1. BioMarin Pharmaceutical Inc.
8.1.1. Company Overview
8.1.2. Key Executives
8.1.3. Company Snapshot
8.1.4. Operating Business Segments
8.1.5. Product Portfolio
8.1.6. Business Performance
8.1.7. Key Strategic Moves and Developments
8.2. Spark Therapeutics, Inc.
8.2.1. Company Overview
8.2.2. Key Executives
8.2.3. Company Snapshot
8.2.4. Operating Business Segments
8.2.5. Product Portfolio
8.2.6. Business Performance
8.2.7. Key Strategic Moves and Developments
8.3. UniQure N.V.
8.3.1. Company Overview
8.3.2. Key Executives
8.3.3. Company Snapshot
8.3.4. Operating Business Segments
8.3.5. Product Portfolio
8.3.6. Business Performance
8.3.7. Key Strategic Moves and Developments
8.4. Pfizer Inc.
8.4.1. Company Overview
8.4.2. Key Executives
8.4.3. Company Snapshot
8.4.4. Operating Business Segments
8.4.5. Product Portfolio
8.4.6. Business Performance
8.4.7. Key Strategic Moves and Developments
8.5. Freeline Therapeutics Holdings Plc.
8.5.1. Company Overview
8.5.2. Key Executives
8.5.3. Company Snapshot
8.5.4. Operating Business Segments
8.5.5. Product Portfolio
8.5.6. Business Performance
8.5.7. Key Strategic Moves and Developments
8.6. Sangamo Therapeutics, Inc
8.6.1. Company Overview
8.6.2. Key Executives
8.6.3. Company Snapshot
8.6.4. Operating Business Segments
8.6.5. Product Portfolio
8.6.6. Business Performance
8.6.7. Key Strategic Moves and Developments
8.7. Bioverativ
8.7.1. Company Overview
8.7.2. Key Executives
8.7.3. Company Snapshot
8.7.4. Operating Business Segments
8.7.5. Product Portfolio
8.7.6. Business Performance
8.7.7. Key Strategic Moves and Developments
8.8. CSL Behring
8.8.1. Company Overview
8.8.2. Key Executives
8.8.3. Company Snapshot
8.8.4. Operating Business Segments
8.8.5. Product Portfolio
8.8.6. Business Performance
8.8.7. Key Strategic Moves and Developments
8.9. Ultragenyx
8.9.1. Company Overview
8.9.2. Key Executives
8.9.3. Company Snapshot
8.9.4. Operating Business Segments
8.9.5. Product Portfolio
8.9.6. Business Performance
8.9.7. Key Strategic Moves and Developments
8.10. Shire Plc
8.10.1. Company Overview
8.10.2. Key Executives
8.10.3. Company Snapshot
8.10.4. Operating Business Segments
8.10.5. Product Portfolio
8.10.6. Business Performance
8.10.7. Key Strategic Moves and Developments
LIST OF TABLES
TABLE 1. GLOBAL HEMOPHILIA GENE THERAPY  MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 2. HEMOPHILIA GENE THERAPY  MARKET FOR HEMOPHILIA A, BY REGION, 2024 - 2033 ($BILLION)
TABLE 3. HEMOPHILIA GENE THERAPY  MARKET FOR HEMOPHILIA B, BY REGION, 2024 - 2033 ($BILLION)
TABLE 4. GLOBAL HEMOPHILIA GENE THERAPY  MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 5. HEMOPHILIA GENE THERAPY  MARKET FOR HOSPITALS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 6. HEMOPHILIA GENE THERAPY  MARKET FOR SPECIALTY CLINICS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 7. HEMOPHILIA GENE THERAPY  MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 8. HEMOPHILIA GENE THERAPY  MARKET, BY REGION, 2024 - 2033 ($BILLION)
TABLE 9. NORTH AMERICA HEMOPHILIA GENE THERAPY  MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 10. NORTH AMERICA HEMOPHILIA GENE THERAPY  MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 11. NORTH AMERICA HEMOPHILIA GENE THERAPY  MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 12. U.S. HEMOPHILIA GENE THERAPY  MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 13. U.S. HEMOPHILIA GENE THERAPY  MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 14. CANADA HEMOPHILIA GENE THERAPY  MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 15. CANADA HEMOPHILIA GENE THERAPY  MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 16. MEXICO HEMOPHILIA GENE THERAPY  MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 17. MEXICO HEMOPHILIA GENE THERAPY  MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 18. EUROPE HEMOPHILIA GENE THERAPY  MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 19. EUROPE HEMOPHILIA GENE THERAPY  MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 20. EUROPE HEMOPHILIA GENE THERAPY  MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 21. FRANCE HEMOPHILIA GENE THERAPY  MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 22. FRANCE HEMOPHILIA GENE THERAPY  MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 23. GERMANY HEMOPHILIA GENE THERAPY  MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 24. GERMANY HEMOPHILIA GENE THERAPY  MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 25. ITALY HEMOPHILIA GENE THERAPY  MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 26. ITALY HEMOPHILIA GENE THERAPY  MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 27. SPAIN HEMOPHILIA GENE THERAPY  MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 28. SPAIN HEMOPHILIA GENE THERAPY  MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 29. UK HEMOPHILIA GENE THERAPY  MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 30. UK HEMOPHILIA GENE THERAPY  MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 31. REST OF EUROPE HEMOPHILIA GENE THERAPY  MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 32. REST OF EUROPE HEMOPHILIA GENE THERAPY  MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 33. ASIA-PACIFIC HEMOPHILIA GENE THERAPY  MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 34. ASIA-PACIFIC HEMOPHILIA GENE THERAPY  MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 35. ASIA-PACIFIC HEMOPHILIA GENE THERAPY  MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 36. CHINA HEMOPHILIA GENE THERAPY  MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 37. CHINA HEMOPHILIA GENE THERAPY  MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 38. JAPAN HEMOPHILIA GENE THERAPY  MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 39. JAPAN HEMOPHILIA GENE THERAPY  MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 40. INDIA HEMOPHILIA GENE THERAPY  MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 41. INDIA HEMOPHILIA GENE THERAPY  MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 42. SOUTH KOREA HEMOPHILIA GENE THERAPY  MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 43. SOUTH KOREA HEMOPHILIA GENE THERAPY  MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 44. AUSTRALIA HEMOPHILIA GENE THERAPY  MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 45. AUSTRALIA HEMOPHILIA GENE THERAPY  MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 46. REST OF ASIA-PACIFIC HEMOPHILIA GENE THERAPY  MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 47. REST OF ASIA-PACIFIC HEMOPHILIA GENE THERAPY  MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 48. LAMEA HEMOPHILIA GENE THERAPY  MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 49. LAMEA HEMOPHILIA GENE THERAPY  MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 50. LAMEA HEMOPHILIA GENE THERAPY  MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 51. BRAZIL HEMOPHILIA GENE THERAPY  MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 52. BRAZIL HEMOPHILIA GENE THERAPY  MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 53. SOUTH AFRICA HEMOPHILIA GENE THERAPY  MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 54. SOUTH AFRICA HEMOPHILIA GENE THERAPY  MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 55. SAUDI ARABIA HEMOPHILIA GENE THERAPY  MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 56. SAUDI ARABIA HEMOPHILIA GENE THERAPY  MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 57. REST OF LAMEA HEMOPHILIA GENE THERAPY  MARKET, BY TYPE, 2024 - 2033 ($BILLION)
TABLE 58. REST OF LAMEA HEMOPHILIA GENE THERAPY  MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 59. BIOMARIN PHARMACEUTICAL INC.: KEY EXECUTIVES
TABLE 60. BIOMARIN PHARMACEUTICAL INC.: COMPANY SNAPSHOT
TABLE 61. BIOMARIN PHARMACEUTICAL INC.: OPERATING SEGMENTS
TABLE 62. BIOMARIN PHARMACEUTICAL INC.: PRODUCT PORTFOLIO
TABLE 63. BIOMARIN PHARMACEUTICAL INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 64. SPARK THERAPEUTICS, INC.: KEY EXECUTIVES
TABLE 65. SPARK THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE 66. SPARK THERAPEUTICS, INC.: OPERATING SEGMENTS
TABLE 67. SPARK THERAPEUTICS, INC.: PRODUCT PORTFOLIO
TABLE 68. SPARK THERAPEUTICS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 69. UNIQURE N.V.: KEY EXECUTIVES
TABLE 70. UNIQURE N.V.: COMPANY SNAPSHOT
TABLE 71. UNIQURE N.V.: OPERATING SEGMENTS
TABLE 72. UNIQURE N.V.: PRODUCT PORTFOLIO
TABLE 73. UNIQURE N.V.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 74. PFIZER INC.: KEY EXECUTIVES
TABLE 75. PFIZER INC.: COMPANY SNAPSHOT
TABLE 76. PFIZER INC.: OPERATING SEGMENTS
TABLE 77. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 78. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 79. FREELINE THERAPEUTICS HOLDINGS PLC.: KEY EXECUTIVES
TABLE 80. FREELINE THERAPEUTICS HOLDINGS PLC.: COMPANY SNAPSHOT
TABLE 81. FREELINE THERAPEUTICS HOLDINGS PLC.: OPERATING SEGMENTS
TABLE 82. FREELINE THERAPEUTICS HOLDINGS PLC.: PRODUCT PORTFOLIO
TABLE 83. FREELINE THERAPEUTICS HOLDINGS PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 84. SANGAMO THERAPEUTICS, INC: KEY EXECUTIVES
TABLE 85. SANGAMO THERAPEUTICS, INC: COMPANY SNAPSHOT
TABLE 86. SANGAMO THERAPEUTICS, INC: OPERATING SEGMENTS
TABLE 87. SANGAMO THERAPEUTICS, INC: PRODUCT PORTFOLIO
TABLE 88. SANGAMO THERAPEUTICS, INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 89. BIOVERATIV: KEY EXECUTIVES
TABLE 90. BIOVERATIV: COMPANY SNAPSHOT
TABLE 91. BIOVERATIV: OPERATING SEGMENTS
TABLE 92. BIOVERATIV: PRODUCT PORTFOLIO
TABLE 93. BIOVERATIV: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 94. CSL BEHRING: KEY EXECUTIVES
TABLE 95. CSL BEHRING: COMPANY SNAPSHOT
TABLE 96. CSL BEHRING: OPERATING SEGMENTS
TABLE 97. CSL BEHRING: PRODUCT PORTFOLIO
TABLE 98. CSL BEHRING: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 99. ULTRAGENYX: KEY EXECUTIVES
TABLE 100. ULTRAGENYX: COMPANY SNAPSHOT
TABLE 101. ULTRAGENYX: OPERATING SEGMENTS
TABLE 102. ULTRAGENYX: PRODUCT PORTFOLIO
TABLE 103. ULTRAGENYX: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 104. SHIRE PLC: KEY EXECUTIVES
TABLE 105. SHIRE PLC: COMPANY SNAPSHOT
TABLE 106. SHIRE PLC: OPERATING SEGMENTS
TABLE 107. SHIRE PLC: PRODUCT PORTFOLIO
TABLE 108. SHIRE PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 1. GLOBAL HEMOPHILIA GENE THERAPY  MARKET, 2024 - 2033
FIGURE 2. SEGMENTATION OF HEMOPHILIA GENE THERAPY  MARKET, 2024 - 2033
FIGURE 3. TOP INVESTMENT POCKET IN HEMOPHILIA GENE THERAPY  MARKET
FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
FIGURE 7. LOW THREAT OF SUBSTITUTION
FIGURE 8. HIGH COMPETITIVE RIVALRY
FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALHEMOPHILIA GENE THERAPY  MARKET
FIGURE 10. GLOBAL HEMOPHILIA GENE THERAPY  MARKET SEGMENTATION, BY TYPE
FIGURE 11. HEMOPHILIA GENE THERAPY  MARKET FOR HEMOPHILIA A, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 12. HEMOPHILIA GENE THERAPY  MARKET FOR HEMOPHILIA B, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 13. GLOBAL HEMOPHILIA GENE THERAPY  MARKET SEGMENTATION, BY END USER
FIGURE 14. HEMOPHILIA GENE THERAPY  MARKET FOR HOSPITALS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 15. HEMOPHILIA GENE THERAPY  MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 16. HEMOPHILIA GENE THERAPY  MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 17. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
FIGURE 18. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
FIGURE 19. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
FIGURE 20. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 21. COMPETITIVE DASHBOARD
FIGURE 22. COMPETITIVE HEATMAP: HEMOPHILIA GENE THERAPY  MARKET
FIGURE 23. TOP PLAYER POSITIONING, 2023
FIGURE 24. BIOMARIN PHARMACEUTICAL INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 25. BIOMARIN PHARMACEUTICAL INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 26. BIOMARIN PHARMACEUTICAL INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 27. SPARK THERAPEUTICS, INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 28. SPARK THERAPEUTICS, INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 29. SPARK THERAPEUTICS, INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 30. UNIQURE N.V.: NET SALES, 2021-2023 ($BILLION)
FIGURE 31. UNIQURE N.V.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 32. UNIQURE N.V.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 33. PFIZER INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 34. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 35. PFIZER INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 36. FREELINE THERAPEUTICS HOLDINGS PLC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 37. FREELINE THERAPEUTICS HOLDINGS PLC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 38. FREELINE THERAPEUTICS HOLDINGS PLC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 39. SANGAMO THERAPEUTICS, INC: NET SALES, 2021-2023 ($BILLION)
FIGURE 40. SANGAMO THERAPEUTICS, INC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 41. SANGAMO THERAPEUTICS, INC: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 42. BIOVERATIV: NET SALES, 2021-2023 ($BILLION)
FIGURE 43. BIOVERATIV: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 44. BIOVERATIV: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 45. CSL BEHRING: NET SALES, 2021-2023 ($BILLION)
FIGURE 46. CSL BEHRING: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 47. CSL BEHRING: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 48. ULTRAGENYX: NET SALES, 2021-2023 ($BILLION)
FIGURE 49. ULTRAGENYX: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 50. ULTRAGENYX: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 51. SHIRE PLC: NET SALES, 2021-2023 ($BILLION)
FIGURE 52. SHIRE PLC: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 53. SHIRE PLC: REVENUE SHARE, BY REGION, 2023 (%)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us